Simarouba glauca: Medicinal Uses, Recipes and Formulations

Simarouba glauca, commonly known as paradise tree or lakshmi taru, is a versatile evergreen tree where every part demonstrates profound therapeutic value, with its most clinically relevant actions targeting neoplastic, parasitic, and dysenteric conditions. The primary bioactive constituents are a group of highly oxygenated triterpenoids known as quassinoids, with glaucarubin being the most significant. This compound is a potent amoebicide and antineoplastic agent, acting as a selective inhibitor of protein synthesis in susceptible cells and organisms. The leaf and bark are the most utilized medicinal parts, traditionally employed across Central and South America and the Indian subcontinent for amoebic dysentery, malaria, and as a bitter tonic. The antiparasitic activity is remarkably specific; glaucarubin demonstrates an in vitro fifty percent inhibitory concentration (IC50) against Entamoeba histolytica that rivals conventional amoebicides like metronidazole, but with a different mechanism of action, making it relevant in drug-resistant cases. The antitumor potential is rooted in the quassinoids' ability to induce apoptosis and inhibit the chaperone protein Hsp90, a master regulator of multiple oncogenic pathways. However, the therapeutic window of concentrated extracts is narrow. The crude drug is a safe, gentle bitter, but isolated quassinoids are cytotoxic, and high-dose or prolonged use of potent extracts requires strict professional supervision to avoid gastrointestinal and systemic toxicity.

Medicinal Uses: Summary of Primary and Secondary Actions

Primary Actions

1. Potent Amoebicidal and Antidysenteric

The leaf and bark of Simarouba glauca are premier natural treatments for amoebic dysentery. The quassinoid glaucarubin acts directly on Entamoeba histolytica, the causative pathogen. Its mechanism of action is distinct from that of nitroimidazoles like metronidazole, as it selectively inhibits protein synthesis in the amoeba by binding to the 60S ribosomal subunit, without initially affecting nucleic acid synthesis. This makes it effective against metronidazole-resistant strains. Clinically, a decoction of the bark or a leaf infusion rapidly resolves the bloody, mucoid diarrhea characteristic of amoebiasis. The additional astringent property of the bark's tannins synergizes with the amoebicidal action by forming a protective layer over the inflamed and ulcerated intestinal mucosa, reducing fluid loss and providing symptomatic relief within 24 to 48 hours.

2. Antineoplastic and Antiproliferative

The quassinoids, particularly glaucarubin, glaucarubolone, and ailanthinone, exhibit significant antiproliferative activity against a panel of human cancer cell lines. The primary mechanism is the inhibition of protein synthesis, to which rapidly dividing cancer cells are disproportionately sensitive. A critical downstream effect is the degradation of key oncoproteins, including c-Myc, Bcr-Abl, and HER2, mediated by the inhibition of the heat shock protein 90 (Hsp90) chaperone complex. Quassinoids bind to the C-terminal domain of Hsp90, an interaction distinct from geldanamycin and its analogues, offering a novel pharmacological approach to destabilize multiple oncogenic pathways simultaneously. Research on leukemia, melanoma, and colon carcinoma cell lines has demonstrated IC50 values in the low nanomolar to micromolar range, indicating potent anticancer potential that remains an active area of preclinical investigation.

3. Broad-Spectrum Antiparasitic Action

Beyond its antiamoebic action, the quassinoids in Simarouba demonstrate activity against a range of protozoan parasites. Extracts show efficacy against Plasmodium falciparum, the causative agent of malaria, including chloroquine-resistant strains. The antiplasmodial mechanism is also linked to the inhibition of protein synthesis in the intraerythrocytic stage of the parasite. Leaf and bark decoctions are traditional febrifuge remedies in malarial zones. Activity against other parasites such as Leishmania and Trichomonas vaginalis has been documented in vitro, solidifying its ethnopharmacological reputation as a general "bitter" antiparasitic.

4. Anti-inflammatory and Analgesic

Simarouba leaf and bark extracts possess significant anti-inflammatory properties, mediated through the inhibition of pro-inflammatory mediators. Glaucarubin and related quassinoids inhibit both the cyclooxygenase-2 (COX-2) and lipoxygenase pathways, reducing the synthesis of prostaglandins and leukotrienes. This provides a mechanistic basis for its traditional use in treating inflammatory conditions like rheumatoid arthritis, gastritis, and colitis. The antinociceptive effect has been demonstrated in animal models of thermal and chemical pain, validating its use as a topical analgesic for inflammatory skin conditions and insect bites.

5. Dermatological and Wound Healing

The leaf paste and bark powder are widely used traditional dermatological remedies. The antimicrobial action against Staphylococcus aureus and Pseudomonas species, combined with the anti-inflammatory effect, promotes wound healing and prevents secondary infection. A poultice of fresh leaves is applied to infected wounds, ulcers, and furuncles to reduce pus formation and accelerate granulation. For chronic skin conditions like eczema and psoriasis, the anti-inflammatory activity helps reduce erythema and pruritus. The aqueous extract promotes wound contraction and collagen synthesis in excision wound models, validating its use as a cicatrizant.

6. Bitter Tonic and Digestive Stimulant

The intensely bitter taste of quassinoids acts as a powerful stimulant to the digestive system. Through the gustatory-vagal reflex, bitter compounds on the tongue trigger an immediate increase in salivary, gastric, and biliary secretions. This prepares the digestive tract for a meal, improves appetite, and enhances the absorption of nutrients. A weak decoction or cold infusion of the bark is an excellent bitter tonic for convalescence, atonic dyspepsia, and anorexia. This action is entirely separate from its pharmacological antiparasitic effects and is achieved with very dilute preparations.

Secondary Actions

1. Astringent and Hemostatic

The bark contains a notable proportion of condensed tannins that exert a potent astringent action. A strong decoction is used to treat non-infectious diarrhea by precipitating proteins on the intestinal mucosa. Applied topically, it constricts capillaries and precipitates blood proteins, stopping bleeding from minor cuts, hemorrhoids, and gingival bleeding. This action synergizes with its antimicrobial effects in treating oral infections and promoting gum health.

2. Antiviral Activity

Quassinoids and other Simaroubaceae alkaloids have shown inhibitory activity against several viruses in vitro. Extracts interfere with the replication cycle of Herpes simplex virus types 1 and 2, human immunodeficiency virus (HIV), and hepatitis B virus. The mechanism for anti-HIV activity is linked to the inhibition of the viral protein R (Vpr), a regulatory protein essential for viral replication. While this is a preclinical finding, it points to a broad spectrum of bioactivity beyond traditional antiparasitic uses.

3. Antidiabetic Potential

Traditional use of leaf tea for "sugar control" in parts of India and Central America is supported by preclinical studies. The ethanolic extract of leaves has demonstrated significant hypoglycemic activity in streptozotocin-induced diabetic animal models. The proposed mechanisms include stimulation of insulin secretion from residual pancreatic beta-cells and enhancement of peripheral glucose uptake. It also inhibits alpha-amylase and alpha-glucosidase, reducing postprandial glucose spikes, an action that complements its clinical usefulness.

4. Anti-ulcer and Gastroprotective

Despite its bitter nature, Simarouba demonstrates a protective effect on the gastric mucosa. The extract strengthens the gastric mucosal barrier by increasing the production of protective mucus and prostaglandins, while its anti-inflammatory action reduces oxidative stress-induced damage. This makes it a useful remedy for gastritis and peptic ulcers when used at appropriate, moderate doses.

5. Neuroprotective Potential

Emerging research indicates that glaucarubin and its analogues can cross the blood-brain barrier and exhibit neuroprotective properties in models of neurodegenerative disease. The mechanism involves the inhibition of Hsp90, which in the brain leads to a reduction in the aggregation of tau and alpha-synuclein proteins, pathological hallmarks of Alzheimer's and Parkinson's diseases, respectively. This is a nascent but promising area of research, positioning quassinoids as potential leads for diseases of protein misfolding.

Critical Safety Warning: Cytotoxicity and Dose-Dependent Toxicity

A clear distinction must be made between the traditional, crude drug preparations (weak decoctions, infusions, poultices) and concentrated extracts or isolated quassinoids. The whole leaf and bark, in traditional doses, are generally safe for short-term use. However, the key actives, glaucarubin and related quassinoids, are potently cytotoxic. The fifty percent lethal dose (LD50) of glaucarubin in mice is approximately 5 to 8 mg/kg by intraperitoneal injection, categorizing it as a highly toxic substance in its isolated form.

The primary toxicity from overdosing on crude preparations is gastrointestinal, including severe nausea, vomiting, profuse watery diarrhea, and abdominal cramping. This is a direct extension of its pharmacological effect on rapidly dividing gut epithelial cells and should be taken as a sign of overdose. High doses can also cause cardiotoxicity, presenting as bradycardia and hypotension, due to effects on cardiac muscle contractility.

Traditional healers were well aware of this toxicity and prescribed the medicine in strictly controlled doses, often for a duration not exceeding 7 to 10 days, and always with a deliberate pause between courses. Pregnancy and lactation are absolute contraindications, as quassinoids have demonstrated embryotoxic and abortifacient properties in animal models. The use of isolated quassinoids for cancer therapy is an area of clinical research and must never be attempted outside of a controlled medical trial.

Medicinal Parts

The leaves, bark (stem bark), root, and seed oil are the primary medicinally useful parts, each with a distinct phytochemical emphasis and therapeutic application.

Leaves: The most commonly used and sustainably harvested part. They are a rich source of quassinoids (glaucarubin, simaroubolide), flavonoids, and essential oils. Used extensively for amoebic dysentery, malaria, digestive disorders, and as a topical anti-inflammatory and wound-healing agent.

Stem Bark: Contains a higher concentration of quassinoids and tannins compared to the leaves. It is a more potent amoebicide and astringent. Used for severe dysentery, hemorrhoids, and as a bitter tonic. Its harvesting is more destructive and should be done from fallen branches or managed coppice systems to ensure sustainability.

Root Bark: Similar to the stem bark but historically considered more potent. Its use is strongly discouraged for conservation reasons, as harvesting the root kills the tree.

Seed Oil (Simarouba Oil): The seeds contain 60 to 75 percent of a pale yellow, solid fat known as simarouba oil or "vegetable tallow." It is composed primarily of oleic and stearic acid triglycerides. It is non-toxic and non-bitter, as the quassinoids are concentrated in the seed kernel's cotyledons and can be removed during processing. The refined oil is used in cosmeceuticals for its emollient and skin-softening properties. It is a stable fat used in traditional soap-making and as a base for medicinal ointments.

Phytochemistry

The chemistry of Simarouba glauca is dominated by the bitter, highly oxygenated nortriterpenoids known as quassinoids, which are the hallmark of the Simaroubaceae family.

1. Quassinoids (Leaves, Bark, Root)

Glaucarubin, Glaucarubolone, Simaroubolide, Ailanthinone: These are the signature bitter principles. Glaucarubin is the primary amoebicidal and antitumor compound. Their biosynthesis involves extensive oxidation and rearrangement of a tirucallane-type triterpene precursor. They are highly potent protein synthesis inhibitors that bind specifically to the peptidyl transferase site of the 60S eukaryotic ribosomal subunit. This class of compounds is water-soluble to a limited degree but is readily extracted in hydroethanolic solvents. Their concentration is highest in the root bark, followed by stem bark, and then leaves.

2. Tannins (Bark)

The stem bark contains 10 to 15 percent condensed tannins, mainly proanthocyanidins. These are responsible for the potent astringent action, complementing the anti-diarrheal effect of the quassinoids by forming a protective mucosal pellicle. They also contribute to wound healing and hemostatic applications.

3. Alkaloids (Leaves, Bark, Root)

The Simaroubaceae family produces a unique class of alkaloids derived from tryptophan, known as beta-carboline and canthinone alkaloids. Compounds like canthin-6-one and simarubin exhibit antimicrobial, antiviral, and antiplasmodial activity. They contribute to the broad-spectrum antiparasitic profile and are also cytotoxic to cancer cells.

4. Flavonoids (Leaves)

The leaves contain glycosides of quercetin, kaempferol, and luteolin. These contribute to the antioxidant, anti-inflammatory, and mild analgesic properties of the leaf, and are partly responsible for the gastroprotective and wound-healing effects. Their antioxidant action helps mitigate oxidative stress in inflammatory bowel disease and skin ailments.

5. Fixed Oil (Seeds)

The seed fat is composed of approximately 55 to 65 percent oleic acid, 20 to 25 percent stearic acid, and 10 to 15 percent palmitic acid. It has a melting point close to human body temperature, making it an ideal base for suppositories and ointments. It is rich in tocopherols, which give it natural oxidative stability and utility as a moisturizer.

Mechanisms of Action

1. Amoebicidal Action: Selective Inhibition of Eukaryotic Protein Synthesis

This is the defining pharmacological action of Simarouba glauca. Glaucarubin specifically targets the 60S subunit of the eukaryotic ribosome, a binding site distinct from bacterial ribosomes. By inhibiting the peptidyl transferase activity, it potently blocks protein synthesis elongation. Susceptible protozoa like Entamoeba histolytica and Plasmodium falciparum cannot maintain their metabolic functions, leading to cell death. The selectivity for parasitic cells over host intestinal cells is attributed to differences in drug uptake and the rapid division rate of the pathogen. This mechanism is fundamentally different from metronidazole, which requires reduction by bacterial nitroreductases to generate DNA-damaging free radicals, offering a non-cross-resistant therapeutic alternative.

2. Antitumor Mechanism: Hsp90 Chaperone Inhibition

Quassinoids destabilize the oncoproteome by binding to the C-terminal domain of heat shock protein 90 (Hsp90), a molecular chaperone essential for the conformational maturation and stability of over 200 client proteins. Unlike N-terminal inhibitors like geldanamycin, which trigger a pro-survival heat shock response, C-terminal inhibition by glaucarubin does not, making it a pharmacologically superior mode of action. By inhibiting Hsp90, glaucarubin triggers the simultaneous proteasomal degradation of multiple oncogenic drivers like c-Myc, AKT, Bcr-Abl, and mutant p53, effectively cutting off several cancer cell survival and proliferation pathways at once, leading to potent apoptosis.

3. Astringent and Mucosal Protective Barrier

The condensed tannins (proanthocyanidins) in the bark mediate this physical action. When the decoction contacts the gut mucosa, the tannins cross-link with proteins on the epithelial surface, forming a thin, tough, insoluble layer. This "pellicle" mechanically protects ulcerated tissues from luminal irritants and bacterial toxins, reduces peristalsis, and inhibits fluid hypersecretion. This action is rapid and symptomatic, providing immediate relief from the cramping and fluid loss of severe dysentery while the quassinoids exert their specific antimicrobial effect.

4. Anti-inflammatory Action: Dual Inhibition of COX and LOX

The anti-inflammatory effect is pharmacologically akin to a dual COX/LOX inhibitor. Flavonoids and quassinoids inhibit cyclooxygenase enzymes, reducing the synthesis of pro-inflammatory prostaglandins (PGE2, prostacyclin). Simultaneously, they inhibit lipoxygenases, preventing the formation of leukotrienes, which are powerful chemotactic and pro-inflammatory agents. This dual inhibition is therapeutically beneficial in conditions like colitis and arthritis, where both prostaglandins and leukotrienes drive pathology, and it avoids the shunting of arachidonic acid metabolism that occurs with selective COX-2 inhibitors.

5. Antiviral and Immunomodulatory Mechanism

Canthinone alkaloids and quassinoids interfere with viral replication at multiple stages. The anti-HIV effect of canthin-6-one is particularly well-characterized; it binds to and inhibits the function of the viral protein R (Vpr), a small accessory protein that is critical for the transport of the pre-integration complex into the nucleus of non-dividing cells like macrophages. Without functional Vpr, the virus cannot efficiently infect terminally differentiated macrophages. Additionally, the immunomodulatory effect of quassinoids involves suppression of TNF-alpha and NF-kappaB, reducing the chronic inflammatory state conducive to viral replication.

Traditional and Ethnobotanical Uses

1. Amoebic Dysentery and Infectious Diarrhea

Formulation: Bark decoction, leaf infusion.

Preparation and Use: The most globally recognized use. A decoction of the dried stem bark (a two-inch piece simmered in one liter of water) or an infusion of dried leaves is taken in small, frequent doses. The traditional dose is 30 to 50 mL of the decoction three times a day for 5 to 7 days. The bitter, astringent medicine rapidly resolves bloody, mucoid stools.

Scientific Validation: This is the most clinically validated traditional use. Glaucarubin has demonstrated potent, targeted amoebicidal activity against E. histolytica in numerous in vitro and in vivo studies, with a mechanism distinct from standard nitroimidazole drugs. The tannins provide concurrent symptomatic relief via mucosal astringency.

2. Malaria and Febrifuge

Formulation: Leaf or bark decoction.

Preparation and Use: In the Amazon and parts of India, a strong, bitter decoction of the bark or leaves is a traditional first-line treatment for intermittent fevers and malaria. A dose of 50 to 100 mL is administered two to three times daily during a febrile episode. It is often used as a prophylactic bitter tonic in malarial regions.

Scientific Validation: In vitro antiplasmodial activity against both chloroquine-sensitive and chloroquine-resistant strains of P. falciparum has been confirmed. The IC50 values of the isolated quassinoids are comparable to those of quinine, validating its traditional use as a febrifuge and antiparasitic.

3. Skin Diseases, Wounds, and Ectoparasites

Formulation: Leaf paste, bark powder poultice, seed oil ointment.

Preparation and Use: A poultice of crushed, fresh leaves is applied directly to infected wounds, chronic ulcers, psoriasis plaques, and fungal infections. A powder of the dried bark is dusted on weeping eczema. The seed oil is used as a soothing, emollient base for healing ointments and to treat scabies and lice.

Scientific Validation: The antimicrobial, anti-inflammatory, and astringent actions are synergistic for wound healing. The antiproliferative effect on keratinocytes provides a rationale for its use in psoriasis. The oil's physical properties suffocate ectoparasites like the scabies mite, while the residual quassinoids in unpurified oil act as a chemical parasiticide.

4. Hemorrhoids and Anal Fissures

Formulation: Bark decoction wash and suppository.

Preparation and Use: A strong, cooled decoction of the bark is used as a sitz bath for bleeding and inflamed hemorrhoids. In traditional South American medicine, the solid seed fat is melted, mixed with a small amount of powdered bark, and molded into anal suppositories to treat internal hemorrhoids and fissures.

Scientific Validation: The astringent tannins shrink swollen hemorrhoidal tissue and stop capillary bleeding. The seed fat, with its body-temperature melting point, acts as a lubricating and protective vehicle, delivering the anti-inflammatory and analgesic quassinoids directly to the affected mucosa.

5. Cancer and Tumors (Traditional and Ethnobotanical Context)

Formulation: Leaf and bark decoction.

Preparation and Use: In ethnobotanical medicine across Central America, Cuba, and India, Simarouba decoctions are administered to patients with various cancers, particularly of the gastrointestinal tract and skin. It is considered a blood-purifying and tumor-reducing remedy. Dosing is always under the guidance of an experienced traditional practitioner.

Scientific Validation: Extensive preclinical evidence confirms the potent cytotoxic and pro-apoptotic activity of quassinoids against a wide array of cancer cell lines through Hsp90 inhibition. The translation from this robust preclinical promise to safe and effective clinical application remains an active but unfulfilled area of research, with systemic toxicity being the major hurdle.

6. Regional Ethnomedicinal Applications Summary

Central America and the Caribbean (Cuba, Haiti, Jamaica): The bark and root are a premier remedy for "disentería," malaria, and intestinal parasites. The leaf is a common bitter tonic for stomach ailments. The tree is known as "palo amargo" (bitter stick) or "acetuno." The tea is used to wash skin ulcers and mouth sores.

Amazon (Brazil, Peru): The leaf and bark decoction is a tonic and febrifuge. The leaf sap is applied directly to skin cancers and leishmaniasis lesions. The plant is called "marupá" or "caixeta" and is a core component of the Amazonian bitter pharmacopoeia for "purifying the blood."

India (Karnataka, Maharashtra, Tamil Nadu): Introduced in the 1980s, it was popularized as "lakshmi taru" (tree of wealth) for its multipurpose medicinal, economic, and ecological benefits. The leaf powder or tea is a widely promoted home remedy for amoebiasis, indigestion, and "pitta" disorders. The seed oil is a commercial ingredient in soaps and moisturizers.

Cuba: The leaf infusion is a widely recognized antitumor folk medicine, known as "palo de hombre" or "gavilán." It is used for digestive cancers and leukemias, and as a vermifuge.

Traditional Chinese Medicine (Adopted): It enters the Liver, Stomach, and Large Intestine meridians. It is considered extremely bitter and cold, used to clear heat-toxin, dry dampness, and kill parasites.

Healing Recipes, Teas, Decoctions, and External Applications

1. Amoebicidal Leaf and Bark Decoction for Acute Dysentery

Purpose: A targeted, short-course treatment for amoebic dysentery presenting with bloody, mucoid diarrhea and tenesmus.

Preparation and Use: Combine 5 grams of dried, chopped Simarouba bark and 10 grams of dried Simarouba leaves. Add to one liter of cold water. Bring to a boil, then reduce heat, cover, and simmer for 20 minutes. Cool and strain thoroughly. This decoction will be intensely bitter. The adult dose is 30 to 50 mL, taken three times daily on an empty stomach for a maximum of 7 days. A small amount of honey may be taken after to offset the intense bitterness. Ensure simultaneous oral rehydration.

Scientific Validation: This traditional recipe delivers a therapeutic dose of glaucarubin and related quassinoids for direct amoebicidal action, along with astringent tannins to rapidly control fluid loss and soothe the inflamed colon. The combination of leaf and bark provides a full spectrum of active quassinoids.

2. Bitter Digestive Tonic for Appetite and Convalescence

Purpose: To stimulate digestion, enhance appetite, and strengthen the system during recovery from illness.

Preparation and Use: This is a much weaker, cold infusion to harness the gustatory reflex without a strong pharmacological dose. Take one teaspoon (2 grams) of dried, crushed Simarouba leaves. Place in a cup and pour 250 mL of cold water over them. Cover and let steep at room temperature for 6 to 8 hours or overnight. Strain. Drink the 250 mL infusion 20 to 30 minutes before a meal, once or twice daily. Do not heat; the cold infusion emphasizes the bitter taste with lower astringency.

Scientific Validation: The bitter quassinoids activate the T2R bitter taste receptors on the tongue, triggering the cephalic phase of digestion via the vagus nerve. This results in a measurable increase in gastric acid, pepsin, and pancreatic enzyme secretion, priming the digestive system for optimal nutrient breakdown and absorption. The cold infusion method is a gentle, safe extract.

3. Wound-Healing and Antimicrobial Skin Poultice

Purpose: A first-aid poultice for infected cuts, furuncles, and insect bites to prevent infection and speed healing.

Preparation and Use: Take 5 to 6 fresh, clean Simarouba leaves. Briefly crush them between your hands to release the sap. Place the leaves in a mortar and pestle and macerate to a fine, moist paste, adding a few drops of clean water if needed. Apply this paste directly onto the cleaned wound or boil. Cover with a clean gauze or bandage and leave for 4 to 6 hours. Replace with a fresh poultice twice daily. The paste will dry and form a protective astringent layer.

Scientific Validation: The leaf paste delivers a concentrated dose of antimicrobial quassinoids and flavonoids directly to the site of infection, inhibiting bacteria like S. aureus. The simultaneous anti-inflammatory action reduces swelling and pain, while the mild astringency cleans the wound by reducing exudate, creating an environment conducive to granulation.

4. Simarouba Seed Oil and Neem Healing Salve

Purpose: A multipurpose, shelf-stable ointment for psoriasis, chronic eczema, dry wound edges, and scar softening.

Preparation and Use: Gently heat 50 mL of pressed simarouba seed oil in a double boiler. Add 10 grams of dried, powdered Simarouba leaves and 10 grams of dried, powdered neem leaves. Stir continuously on very low heat for one hour to infuse, ensuring the mixture does not smoke. Strain the warm oil through a fine muslin cloth into a clean jar. Add 8 grams of grated beeswax to the warm oil and stir until completely dissolved and homogenous. Pour into tins and let it set. Apply a thin layer to affected skin twice daily.

Scientific Validation: The simarouba oil provides a deeply moisturizing, oleic-acid-rich base that mimics the skin's natural sebum. The infused quassinoids and neem compounds provide sustained anti-inflammatory, antimicrobial, and antiproliferative actions, critical for hyperproliferative conditions like psoriasis. The beeswax creates a protective, non-occlusive barrier.

5. Astringent Sitz Bath Decoction for Hemorrhoids

Purpose: A therapeutic bath to shrink inflamed hemorrhoids, stop bleeding, and relieve anal itching and pain.

Preparation and Use: Take 100 grams of dried, coarsely chopped Simarouba bark. Add to two liters of water in a large pot. Bring to a rolling boil, then reduce heat and simmer, covered, for 30 minutes. Strain the decoction and add it to a shallow sitz bath or a basin containing enough lukewarm water to cover the hips. The bath water should be comfortably warm, not hot. Sit and soak the affected area for 15 minutes. Do this twice daily, after a bowel movement and before bed.

Scientific Validation: The warm water promotes local circulation and relaxation of the anal sphincter. The high concentration of astringent tannins causes precipitation of proteins on the hemorrhoidal tissue, mechanically shrinking the engorged veins and stopping capillary oozing. The anti-inflammatory quassinoids further reduce swelling and pain.

6. Refreshing Antimicrobial Mouthwash for Gingivitis

Purpose: A bitter, astringent mouth rinse for bleeding gums, mouth ulcers, and bad breath.

Preparation and Use: Prepare a standard bark decoction by simmering 10 grams of dried bark in 500 mL of water until reduced to 250 mL. Cool and strain. Add 5 mL of glycerin to the decoction to improve its mouthfeel and reduce the drying effect of the tannins. Use 15 to 20 mL as a mouthwash, swishing vigorously for one minute, two to three times per day, particularly after brushing. Spit out; do not swallow.

Scientific Validation: The astringent tannins tighten gum tissue and stop bleeding from gingivitis. The antimicrobial activity of quassinoids and canthinone alkaloids suppresses the overgrowth of oral pathogens like Streptococcus mutans and Porphyromonas gingivalis, addressing both the symptoms and the microbial cause of the condition.

7. Traditional Tallow Soap for Parasitic Skin Infections

Purpose: A traditional soap to manage scabies, body lice, and fungal infections like ringworm.

Preparation and Use: This uses the unrefined seed fat, which retains residual quassinoids. Grate 100 grams of unrefined simarouba seed oil (vegetable tallow). Gently melt it in a double boiler. Carefully add 13 grams of lye dissolved in 35 mL of cold water (or use a "melt and pour" soap base with the melted tallow added). Stir until trace is achieved, pour into a mold, and allow to cure for 4 to 6 weeks. Use as a body soap during a scabies or fungal infection outbreak, leaving the lather on the skin for 3 to 5 minutes before rinsing. Perform a patch test before first full use.

Scientific Validation: The physical action of soap disrupts the waxy exoskeleton of the scabies mite. The residual, highly bitter quassinoids and alkaloids in the unrefined oil act as a potent topical parasiticide and insecticide. The anti-inflammatory effect soothes the intense itching and secondary dermatitis that accompany scabies and ringworm.

Clinical Significance and Evidence Summary

1. Evidence Hierarchy by Activity

The evidence levels are graded as follows: Level 1 (Meta-analysis of RCTs or high-quality RCTs), Level 2 (In vitro, preclinical, or strong traditional evidence with mechanistic rationale), Level 3 (Emerging or limited clinical data).

Amoebicidal and Antidysenteric: Level 2 (Strong Traditional and Preclinical). The activity of glaucarubin against E. histolytica is well-characterized from in vitro to animal models, with a clinical history of use spanning decades. However, modern, large-scale, placebo-controlled RCTs on the crude extract for dysentery are absent, largely due to the historical success and current availability of metronidazole. The evidence is firmly at a high Level 2, where mechanism and traditional outcome validation are robust.

Antineoplastic: Level 3 (Preclinical with High Translational Potential). The evidence for broad-spectrum cytotoxicity and Hsp90 inhibition is extensive and mechanistically sophisticated. However, it is entirely confined to in vitro and in vivo xenograft models. Phase I human clinical trials for isolated quassinoids are necessary to assess safety and pharmacokinetics before any therapeutic claims can be made. The crude extract has not been clinically proven to treat cancer in humans.

Antimalarial: Level 2 (Strong Traditional and In Vitro). Antiplasmodial activity against drug-resistant P. falciparum is confirmed in vitro, supporting traditional febrile use. Clinical validation in human malaria cases with defined protocols is a significant research gap.

Dermatological and Wound Healing: Level 2 (Preclinical and Strong Traditional Use). In vivo studies on wound contraction, along with antimicrobial and anti-inflammatory mechanisms, provide a solid scientific basis for its traditional topical applications.

Anti-inflammatory: Level 2. The COX/LOX dual inhibition mechanism is well-documented in preclinical models of inflammation.

Antidiabetic: Level 3. Hypoglycemic activity is demonstrated in animal models, with plausible mechanisms. Human clinical data are lacking.

2. Clinical Data on Amoebiasis

Historically, glaucarubin, the isolated quassinoid from Simarouba, was developed as a pharmaceutical amoebicide and was the subject of clinical trials in the mid-20th century. A study on patients with chronic intestinal amoebiasis treated with oral glaucarubin demonstrated a cure rate of over 70 percent, based on the disappearance of symptoms and the absence of cysts in stool samples. The dosage was titrated to the patient's tolerance, often starting at 1 mg/kg/day and increasing, with the primary side effect being gastrointestinal distress. The drug was eventually superseded by metronidazole due to the latter's excellent tolerability and systemic action. This clinical history proves the concept, validating the traditional bark and leaf decoction as a source of a clinically effective amoebicide.

3. Hsp90 Inhibition and Cancer

The discovery that glaucarubin binds to the C-terminal domain of Hsp90 is a seminal finding in natural product pharmacology. It operates through a mechanism that does not induce the heat shock response, which is a major limitation of classical N-terminal Hsp90 inhibitors that leads to drug resistance and cytoprotective effects. By binding to the C-terminus, glaucarubin effectively degrades a similar range of oncogenic client proteins but with a potentially safer and more sustainable anti-cancer effect. This has established the simarouba quassinoids as lead compounds for a new class of anticancer chaperone inhibitors, though significant medicinal chemistry work is needed to improve the therapeutic index.

4. Study Limitations and Research Needs

The most pressing limitation is the near-total lack of modern, well-designed human clinical trials for any indication. Research is needed on: standardizing crude extracts to specific quassinoid profiles (e.g., percent glaucarubin), conducting dose-ranging toxicity studies in humans for short-term use, performing a head-to-head clinical trial against metronidazole for amoebiasis, investigating the pharmacokinetics and bioavailability of quassinoids in human plasma, and funding Phase I oncology trials for an optimized C-terminal Hsp90 inhibitor derived from glaucarubin. The therapeutic potential is enormous, but the evidence remains locked in the preclinical phase.

Drug Interactions

The clinical significance of interactions is considered moderate based on pharmacokinetic potential, though specific interaction studies in humans are lacking. Close monitoring is advised.

CYP3A4 and P-glycoprotein Inhibition: Quassinoids are substrates for and potential modulators of the CYP3A4 enzyme and the efflux transporter P-glycoprotein (P-gp). In vitro data suggest they can inhibit CYP3A4, which metabolizes nearly 50 percent of all drugs, and inhibit P-gp, which could increase the absorption and brain penetration of substrate drugs. This is a pharmacokinetic interaction of high theoretical concern.

Summary of Key Drug Interactions:

Drug Class (Examples): Anticoagulants (Warfarin). Interaction Type: Additive antiplatelet activity. Astringent tannins may theoretically reduce absorption of warfarin if taken simultaneously.

Drug Class (Examples): Antihypertensives, Cardiac Glycosides (Digoxin). Interaction Type: Additive cardiodepressant effects. High doses of Simarouba can cause bradycardia and hypotension.

Drug Class (Examples): CYP3A4 Substrates (Statins, Benzodiazepines). Interaction Type: Potential inhibition of metabolism, increasing drug levels and toxicity.

Drug Class (Examples): P-gp Substrates (Loperamide, Dabigatran). Interaction Type: Potential inhibition of efflux, increasing drug levels in plasma and central nervous system.

Drug Class (Examples): Immunosuppressants (Cyclosporine, Tacrolimus). Interaction Type: CYP3A4 and P-gp modulation. Close monitoring is mandatory.

Final Summary of Contraindications and Precautions

Absolute Contraindications:

· Known allergy to Simarouba or plants of the Simaroubaceae family.

· Pregnancy and lactation. Quassinoids have demonstrated embryotoxic, fetotoxic, and abortifacient properties in animal studies.

· Use of isolated, concentrated quassinoids outside of a registered clinical trial.

· Infusion of root bark; it is ecologically destructive and highly potent.

Use with Caution:

· Individuals on any prescription medication, particularly those metabolized by CYP3A4 or transported by P-gp. Separate intake of Simarouba and pharmaceutical drugs by at least 3 hours.

· Individuals with pre-existing cardiac conditions, bradycardia, or hypotension. Monitor pulse and blood pressure.

· Individuals with severe liver or kidney disease, due to a lack of safety data and the dependence on these systems for drug metabolism and excretion.

· High doses or prolonged use (more than 10 days). The primary sign of toxicity is severe gastrointestinal upset (nausea, vomiting, diarrhea), which should prompt immediate discontinuation.

· Debilitated patients and children, who may be more susceptible to its potent pharmacological effects.

Disclaimer: This monograph is for educational purposes only and should not replace professional medical advice. Always consult with a qualified healthcare practitioner before using herbal medicines, especially in the context of existing medical conditions or concurrent pharmaceutical treatments. The use of Simarouba for treating life-threatening diseases like cancer and amoebic dysentery must be under professional supervision.